)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Aytu Biopharma
Aytu Biopharma (AYTU) investor relations material
Aytu Biopharma Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary17 Mar, 2026
Strategic realignment and business focus
Shifted to a profitable prescription pharmaceutical business, exiting consumer health and pipeline R&D, with a $34.7M adjusted EBITDA improvement over four years.
Key events include suspension of clinical programs, refinancing of term loan, outsourcing manufacturing, divesting consumer health, and launching EXXUA for MDD.
Product portfolio and innovation
Focuses on novel, patent-protected prescription brands for CNS conditions, especially MDD and ADHD.
EXXUA is the first and only selective 5-HT1A agonist approved for MDD in adults, offering a unique mechanism of action and favorable side effect profile.
ADHD and pediatric brands include Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor.
Commercial infrastructure and patient access
Proprietary Aytu RxConnect program ensures broad, affordable access and high patient adherence, supported by a nationwide pharmacy network.
Lean, scalable commercial infrastructure with a direct sales force and analytics platform enables rapid expansion and targeted promotion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aytu Biopharma
- Q2 FY2026 net revenue was $15.2M, net loss $10.6M, as Exxua launch drives strategic shift.AYTU
Q2 20263 Feb 2026 - EXXUA launch and business realignment drive revenue growth and profitability.AYTUCorporate presentation3 Feb 2026
- Prescription focus, RxConnect, and operational streamlining drive robust growth and profitability.AYTUSidoti Micro-Cap Virtual Conference2 Feb 2026
- A differentiated MDD therapy launches with strong efficacy, safety, and scalable execution.AYTUInvestor Day 202620 Jan 2026
- ADHD revenue and margins rose in 2024, driving optimism for Rx segment growth in 2025.AYTUQ4 202420 Jan 2026
- Strong ADHD growth, RxConnect platform, and international expansion drive robust performance.AYTUMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- Exxua's launch leverages unique differentiation and RxConnect to target major growth in depression treatment.AYTU2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026
- EXXUA's Q4 2025 launch targets major MDD market growth, leveraging strong financial momentum.AYTUCorporate presentation15 Jan 2026
- First positive net income of $1.5M and continued EBITDA growth amid portfolio and cost gains.AYTUQ1 202514 Jan 2026
Next Aytu Biopharma earnings date
Q3 202613 May, 2026
Aytu Biopharma
Next Aytu Biopharma earnings date
Q3 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage